Early pregnancy is a delicate process of coordination, requiring a secure connection between the developing embryo and the mother’s blood supply. Guiding this crucial step is a specialized group of immune cells known as uterine natural killer cells, or uNK cells. Now, a recent peer-reviewed study from the University of Alabama at Birmingham (UAB) has identified a critical “immune switch” – NFAT – that governs the ability of these cells to grab up residence in the uterus and support early placental growth. Disruptions to this process, when the NFAT switch is “turned down,” may lead to pregnancy complications.
The findings, published today in Science Translational Medicine, offer a fresh perspective on the complex interplay between the immune system and successful pregnancy. Researchers discovered that NFAT controls whether uNK cells become “tissue-resident,” a necessary step for remodeling maternal blood vessels and fostering early placental development. This discovery could have implications for understanding and potentially preventing conditions like preeclampsia, implantation failure, and early pregnancy loss.
“Seeing NFAT act as a residency switch in uterine NK cells was a surprise,” said Paige Porrett, M.D., Ph.D., lead author of the study and professor of surgery and obstetrics and gynecology, as well as the Vera Hauptfeld‑Dolejsek Endowed Professor of Transplant Immunology at UAB’s Heersink School of Medicine. “It gives us a concrete lead on why some pregnancies veer toward complications and opens up a whole new world of research.”
The research builds on UAB’s expertise in uterus transplantation, providing a unique opportunity to study the immune environment during pregnancy. Although, Porrett emphasized that the underlying mechanism appears to be fundamental to human placental development, potentially impacting all pregnancies, not just those involving transplant recipients. “This isn’t just a transplant story,” she stated. “We used transplant as a lens, but the biology may map onto normal pregnancies and high-risk ones. The benefits of this work are potentially for all pregnant patients.”
How NFAT Influences Uterine NK Cell Residency
UAB scientists found that NFAT is essential for uNK cells to become tissue-resident, allowing them to remain within the uterine lining and effectively remodel maternal blood vessels – a critical step for early placental growth. Prior to this study, NFAT’s role was well-established in T cells, but its function within uterine NK cells and its connection to pregnancy had remained unknown. “This represents a new pathway for immune cells to become resident that we didn’t recognize about before,” Porrett explained. “We now show in humans that the biology we’ve only ever seen in mice applies.”
The team utilized single-cell RNA sequencing, a cutting-edge technology that measures gene activity in individual cells, to achieve this level of detail. This allowed researchers to observe shifts in gene programs across thousands of cells, something older methods couldn’t capture in the dynamic environment of the uterus. “Single-cell sequencing let us see, cell by cell, the gene programs that were changing,” Porrett said. “You need that granularity to identify a pathway like this.”
Implications for Immunosuppressive Medications
The study also raises important questions about the apply of tacrolimus, a commonly prescribed immunosuppressive medication for solid-organ transplant recipients. While tacrolimus is effective in preventing organ rejection – and previous research has indicated it doesn’t increase the risk of birth defects – the new findings suggest that lowering the NFAT signal with this medication may potentially increase the risk of placental complications.
“Tacrolimus works incredibly well, but now we’ve identified a biological reason to reconsider how we use it during pregnancy,” Porrett said. “We have to do the hard work of finding safer alternatives for pregnant patients while still preventing rejection.” Researchers stress that no changes to medication regimens should be made based solely on this study. Instead, the findings provide a foundation for future research focused on identifying alternative drugs or timing strategies that can protect both the pregnancy and the transplanted organ.
“It’s a balance,” Porrett added. “Tacrolimus is a workhorse, and any change must be evidence-based.”
Future Research Directions
Beyond its implications for transplant recipients, this research opens new avenues for understanding pregnancy complications in individuals who are not immunocompromised. The UAB team plans to investigate how immunosuppressive drugs affect other immune and non-immune cell types within the uterus, including stromal and epithelial cells, to gain a more comprehensive understanding of the biological landscape. “These human data are powerful, but they’re largely associative,” Porrett noted. “We need to validate causality and understand how other uterine cell types respond. That’s the hard work ahead – and it’s how we turn a discovery into better outcomes.”
The research was supported by grants from the National Institutes of Health (R01AI177369, R01AI145905, and R01CA208353), the UAB Center for Women’s Reproductive Health, UAB AMC21 grants, startup funding from the UAB Heersink School of Medicine, and American Cancer Society Research Scholar Grants (#RSG-23-1153857-01-IBCD, F31HD114429, and T32GM135028).
Disclaimer: This article provides informational content and should not be considered medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
This groundbreaking research offers a new understanding of the immune mechanisms crucial for a healthy pregnancy. Further investigation will be essential to translate these findings into improved clinical outcomes for all expectant mothers. What are your thoughts on this new discovery? Share your comments below.
